Nectar Lifesciences logo

Nectar Lifesciences financials and balance sheet

NSE: NECLIFEBSE: 532649Pharmaceuticals & BiotechnologySmall Cap

Last close ₹10.28down ₹0.48 (4.46%)BSE ₹10.33

Share price at the NSE close on 23 Oct 2026. Previous close ₹10.76.

52-week range of traded prices to 23 Oct 2026
₹9.30Low, 30 Mar 2026₹22.40High, 23 Dec 2025
Market cap
₹200 Cr2,221st largest listed
P/E
Lossover the last 12 months
P/B
0.3
Dividend yield
Nonein the last 12 months
ROE
−31.9%
ROE without one-offs
−9.6%
ROCE
−15.4%
Debt to equity
0.00
Volume, NSE
1,01,72181.0% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Nectar Lifesciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
A loss in 4 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out.

The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty. From the year to Mar 2026, the company reports a discontinued business.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Employee costs−1.9
  2. Other expenses−59
  3. Depreciation−0.3
  4. Other income+9.3
  5. One-off items0.0
  6. Finance costs−36
  7. Profit before tax−88
  8. Tax+31
  9. Discontinued businesses−236
  10. Net profit−293

What the company owns

  • Plant, investments and other assets₹496 Cr
  • Cash and bank₹112 Cr
  • Current investments₹13 Cr
  • Inventory₹0 Cr

What pays for it: net worth and liabilities

  • Net worth₹582 Cr
  • Other liabilities₹39 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Nectar Lifesciences quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 29 MayMar 2020Filed 1 AugMar 2021Filed 23 JulMar 2022Filed 13 JunMar 2023Filed 26 MayMar 2024Filed 17 MayMar 2025Filed 8 JulMar 2026Filed 30 May
Revenue from operations1,7441,9012,7832,3671,5441,6691,5251,6861,673–
1,5201,6642,5192,1471,4341,5101,4711,5331,70061
Materials and goods bought1,1541,3672,2181,8591,1571,2231,1591,2021,3680
Employee costs––808173757885962
Other expenses––22120720421323424623559
Operating profit before depreciation22523726422011015954153−26–
Operating margin12.9%12.4%9.5%9.3%7.1%9.5%3.5%9.1%−1.6%–
Materials, % of revenue––79.7%78.5%74.9%73.3%76.0%71.3%81.8%–
Employee costs, % of revenue––2.9%3.4%4.8%4.5%5.1%5.0%5.8%–
Other expenses, % of revenue––7.9%8.7%13.2%12.7%15.3%14.6%14.0%–
Depreciation and amortisation6264636160575961620
Operating profit after depreciation16217220115950102−592−89–
Other income22664311421329
Finance costs1171151481261127979877536
Profit before one-off items and tax67635937−5934−4218−162−88
One-off items0000−2500000
Profit before tax67635937−8534−4218−162−88
1210116−129−1813−48−31
Profit from discontinued businesses–––––––––−236
Net profit55524832−7325−245−114−293
Other comprehensive income––01011010
Total comprehensive income––4832−7326−235−113−293
Net margin3.2%2.7%1.7%1.3%−4.7%1.5%−1.6%0.3%−6.8%–
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2017 and Mar 2018 they do not, so they are left blank. Revenue from operations, operating profit before depreciation and operating profit after depreciation are left blank for the year to Mar 2026: the filing states revenue as 0 for a year whose own quarters state revenue, a placeholder rather than a figure, so revenue and what is made from it are not held.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 29 MayMar 2020Filed 1 AugMar 2021Filed 23 JulMar 2022Filed 13 JunMar 2023Filed 26 MayMar 2024Filed 17 MayMar 2025Filed 8 JulMar 2026Filed 30 May
1,1051,1361,0621,0881,0651,069956582
Share capital2222222222222219
Reserves1,0831,1141,0401,0651,0421,047934563
8027418408607546365820
1,3001,2481,1871,0048919731,02226
300249222299234149709
Liabilities going with businesses held for sale–––––––4
2,7052,6332,4712,3912,1892,1912,047622
1,0361,0181,2321,036958907810333
1,6691,6151,2391,3551,2311,2841,238253
Net debt780720814842736615562−125
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 23 JulMar 2022Filed 13 JunMar 2023Filed 26 MayMar 2024Filed 17 MayMar 2025Filed 8 JulMar 2026Filed 30 May
2195134225169−349
2595134225169−349
−47−657871193184
Receivables25−71168−10133316
Inventories139−3313−28146233
Payables−18534−5810118−342
Other working capital−264−45100−5−23
Tax paid−400000
Capital spending312530294412
Free cash flow−1070104195126−361
−291752−17−421,208
11−119−186−205−128−767
Dividends paid100000
Shares bought back0000081
Shares issued000000
Net change in cash4−802−193
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Nectar Lifesciences dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 29 MayMar 2020Filed 1 AugMar 2021Filed 23 JulMar 2022Filed 13 JunMar 2023Filed 26 MayMar 2024Filed 17 MayMar 2025Filed 8 JulMar 2026Filed 30 May
Earnings per share₹2.47₹2.33₹2.12₹1.42−₹3.27₹1.12−₹1.08₹0.22−₹5.07−₹13.40
Diluted earnings per share₹2.47₹2.33₹2.12₹1.42−₹3.27₹1.12−₹1.08₹0.22−₹5.07−₹13.40
Dividend per share₹0.05₹0.05₹0.05₹0.05––––––
Book value per share––₹49.28₹50.66₹47.36₹48.51₹47.47₹47.68₹42.63₹29.97
Dividend payout2.0%2.1%2.4%3.5%––––––
Shareholder yield––––0.3%0.0%0.0%0.0%0.0%44.8%
Market cap at the year end (₹ crore)787589387220417539358676515181

Ratios

Consolidated, years to March.Nectar Lifesciences PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 29 MayMar 2020Filed 1 AugMar 2021Filed 23 JulMar 2022Filed 13 JunMar 2023Filed 26 MayMar 2024Filed 17 MayMar 2025Filed 8 JulMar 2026Filed 30 May
Revenue growth4.1%––−15.0%−34.7%8.1%−8.6%10.6%−0.7%–
Operating profit growth−18.2%5.3%11.7%−16.7%−50.0%44.0%−66.0%183.8%––
Net profit growth−6.5%−5.5%−8.9%−33.2%––––––
Earnings per share growth–−5.7%−9.0%−33.0%––––––
––4.3%2.8%−6.7%2.3%−2.2%0.5%−11.2%–
–––−1.5 pts−9.5 pts9.0 pts−4.6 pts2.7 pts−11.7 pts–
From the net margin–––−0.9 pts−12.9 pts8.8 pts−4.8 pts2.7 pts−11.2 pts–
From asset turnover–––−0.5 pts3.2 pts0.3 pts0.1 pts0.1 pts−0.3 pts–
From borrowing–––−0.1 pts0.2 pts−0.1 pts0.1 pts0.0 pts−0.2 pts–
Return on capital employed––10.5%8.5%2.6%5.2%−0.3%5.4%−5.8%–
Cash conversion–––––379.3%–4,498.6%––
Interest cover1.41.51.41.30.41.3–1.1––
Debt to equity––0.730.650.790.790.710.590.610.00
Receivable days––73618998678275–
Inventory days––151192185197212215184–
Payable days––87104108112100127117–
Cash conversion cycle, days––137150166182178170143–
Working capital days––129149174197203170157–
Asset turnover––1.030.890.610.690.670.770.79–
Assets per rupee of net worth––2.452.382.322.262.132.052.091.73
Sales per rupee of plant––3.543.172.112.452.492.862.900.00
Capital spending to depreciation––––0.520.440.510.480.7035.83
Plant being built, % of plant in use––12.7%15.4%13.4%12.5%12.7%11.1%9.8%0.0%
Revenue growth is left blank for the years to Mar 2018 and Mar 2019: between the two periods excise duty was taken out of revenue when GST replaced it, so the two are on different bases and the change is not worked out. Interest cover is left blank for the years to Mar 2023 and Mar 2025: operating profit after depreciation is a loss, and a loss covers no interest bill. Interest cover is left blank for the year to Mar 2026: the filing states revenue as 0 for a year whose own quarters state revenue, a placeholder rather than a figure, so revenue and what is made from it are not held. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
−21.9%
Measure10 years5 years3 years
Return on equity, average–−2.7%−5.4%
Return on capital employed, average–1.1%−0.2%
Operating margin, average8.0%5.1%3.8%
Net margin, average−0.3%−1.6%−3.2%
Asset turnover, average–0.730.78
Cash conversion cycle, days, average–168156
Debt to equity, average–0.540.40

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations27445−349
Cash from investing1,2181,1491,208
Cash from financing−1,405−1,100−767
Capital spending1418512
Dividends paid000
Shares bought back818181
Shares issued for cash000
Borrowings raised17000
Borrowings repaid1,136821649

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––48584–
Altman Z-scorePublished threshold 1.81––2.151.951.451.901.802.131.734.19
Beneish M-scorePublished threshold −1.78––––−2.36−2.57−3.13−2.76−3.02–
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––−2.59−3.56−9.15−9.25−11.38−86.35
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––––77.38––
Receivables growth less revenue growthOur threshold 0 percentage points–––−14.1929.4311.19−28.8025.05−8.140.00
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––22.68−2.126.547.151.73−16.470.04
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––2.101.94−1.222.06−5.130.42–
Assets under construction, years of additionsOur threshold 2 years of additions–––5.532.0524.17–1.711.17–
Effective tax ratePublished threshold 17.16 per cent17.9216.6119.0815.16–26.51–72.66––
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––26.51–72.66––
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
2 Mar 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-Forward ContractCARE A4 (Rating Watch with Negative Implications); ISSUER NOT COOPERATING*Review, Re-affirm5
2 Mar 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Working Capital Term LoanCARE B+ (Rating Watch with Negative Implications); ISSUER NOT COOPERATING*Review, Downgrade40.15
2 Mar 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Working Capital Demand loanCARE B+ (Rating Watch with Negative Implications); ISSUER NOT COOPERATING*Review, Downgrade31.56
2 Mar 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Term LoanCARE B+ (Rating Watch with Negative Implications); ISSUER NOT COOPERATING*Review, Downgrade95.71
2 Mar 2026CARE Ratings Limited (opens in a new tab)Non-fund-based - ST-BG/LCCARE A4 (Rating Watch with Negative Implications); ISSUER NOT COOPERATING*Review, Re-affirm352.44
2 Mar 2026CARE Ratings Limited (opens in a new tab)Fund-based - LT-Cash CreditCARE B+ (Rating Watch with Negative Implications); ISSUER NOT COOPERATING*Review, Downgrade405.14
16 Jan 2026Brickwork Ratings India Private Limited (opens in a new tab)Bank Loan RatingsLong and short-term scalesBWR B-/BWR A4Review, Re-affirmNegative1,215.91
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.